Pharmacotherapy versus T lymphocytes for CMV

Blood. 2013 May 2;121(18):3544-5. doi: 10.1182/blood-2013-03-487249.


In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV)-specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.

Publication types

  • Comment

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / immunology*
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • T-Lymphocytes / transplantation*
  • Tissue Donors*


  • Antiviral Agents